Chemoradiotherapy is a treatment that combines chemotherapy with radiation therapy. Also called chemoradiation.
In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care investigated whether nivolumab has an added benefit over watchful waiting in the adjuvant treatment of adults with carcinoma of the esophagus or the gastroesophageal junction and pathological residual disease after prior neoadjuvant chemoradiotherapy (CRT).
Japanese researchers identified chromosome aberrations as a new biomarker in predicting an esophageal cancer patient's risk of experiencing severe chemoradiotherapy side effects.
Houston Methodist Neurological Institute researchers from the department of neurosurgery shrunk a deadly glioblastoma tumor by more than a third using a helmet generating a noninvasive oscillating magnetic field that the patient wore on his head while administering the therapy in his own home.
Elderly patients (70 years and over) with locally advanced esophageal (E) and esophagogastric junction (EGJ) cancer (located in the stomach and esophagus) should be considered for optimal therapy that has the potential to cure.
Oncotarget recently published "PD-1/PD-L1 expression in anal squamous intraepithelial lesions" which reported that the presence and distribution of CD8 lymphocytes and the presence of PD-1 lymphocytes and PD-L1 epithelial cells were assessed.
Leukemias and lymphomas are life-threatening malignancies affecting white blood cells and the immune system; fortunately, radiotherapy and chemotherapy, combined with stem cell therapy, can improve survival significantly.
Houston Methodist researchers found that mice harboring human glioblastoma tumors in their brains had greatly enhanced survival and weight gain when given a newly developed prodrug.
A new bioluminescent reporter that tracks DNA double stranded break repair in cells has been developed by researchers from Massachusetts General Hospital and the Academia Sinica in Taiwan.
An international panel of cancer experts has recommended a one-week course of radiotherapy and delaying surgery as the best way to treat patients with bowel cancer during the COVID-19 pandemic.
A new phase II trial finds that a combination of radiation therapy and immunotherapy led to encouraging survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma
A team of doctors and scientists from the Champalimaud Clinical Centre in Lisbon, Portugal, and the Netherlands Cancer Institute in Amsterdam, has shown that patients with "low" rectal cancer (that is, very close to the anus) who show no sign of their tumors after a course of radio- and chemotherapy can safely choose to postpone invasive and complication-prone surgical procedures.
Lung cancer is the leading cause of cancer death in the United States and approximately 75-80% of all cases are non-small cell lung cancer (NSCLC).
Results from the NRG Oncology phase I clinical trial NRG-GOG 9929 show that utilizing the immunotherapy drug ipilimumab after chemoradiotherapy (CRT) is tolerated in the curative treatment of women with lymph node-positive cervical cancer.
The UK is all set to launch its run into the future as the undisputed leader in the field of personalized and effective radiation therapy. The proposal is undergirded by a whopping £56 million, which will be used to set up and fund advanced radiation therapy research by a new collaborative setup, Cancer Research UK RadNet, over five years. This is the largest sum ever invested by this organization into radiotherapy research.
Researchers from Charité - Universitätsmedizin Berlin and the German Cancer Consortium have successfully solved a longstanding problem in the diagnosis of head and neck cancers.
Researchers at Trinity College Dublin have identified, for the first time in esophageal cancer, the cancer killing capability of a lesser-known type of immune cell, presenting a new potential therapeutic target.
Using a new blood test that's in development, University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection.
A recent, updated predictive analysis of the three WHO-defined molecular subgroups based on isocitrate dehydrogenase 1/2 (IDH) mutation status and 1p/19q co-deletion status represented in the high-risk treatment arms of the NRG Oncology clinical trial NRG-RTOG 9802 indicates that both IDH-mutant sub-groups (IDHmut-noncodel and IDHmut-codel) could benefit from the addition of PCV chemotherapy to radiotherapy treatment.
A new special edition of the International Journal of Radiation Oncology* Biology* Physics focuses on the roles of imaging in radiation oncology. The collection explores topics such as improving accuracy with patient positioning, defining radiation therapy volumes using imaging, imaging of functional biomarkers, the role of imaging in post-treatment care, machine learning and artificial intelligence.
The European Society of Coloproctology has undertaken a major international audit of colorectal operations to understand which are most widely used techniques across the world, which appear to be associated with the best outcomes and where further research needs to be undertaken.